|
1
|
International Agency for Research on
Cancer (IARC). GLOBOCAN report. 2018..Retrieved from. simplehttps://www.iarc.fr/
|
|
2
|
Centers for Disease Control and Prevention
(CDC), Division of Cancer Prevention and Control. Breast Cancer
Statistics. 2019.Retrieved from. simplehttps://www.cdc.gov/cancer/breast/basic_info/index.htm
|
|
3
|
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z,
Zhang L, Ji X, Liu W, Huang B, Luo W, et al: Breast cancer
development and progression: Risk factors, cancer stem cells,
signaling pathways, genomics, and molecular pathogenesis. Genes
Dis. 5:77–106. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma GN, Dave R, Sanadya J, Sharma P and
Sharma KK: Various types and management of breast cancer: An
overview. J Adv Pharm Technol Res. 1:109–126. 2010.PubMed/NCBI
|
|
5
|
Akram M, Iqbal M, Daniyal M and Khan AU:
Awareness and current knowledge of breast cancer. Biol Res. 50:33.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Zijl F, Krupitza G and Mikulits W:
Initial steps of metastasis: Cell invasion and endothelial
transmigration. Mutat Res. 728:23–34. 2011. View Article : Google Scholar
|
|
7
|
Seyfried TN and Huysentruyt LC: On the
origin of cancer metastasis. Crit Rev Oncog. 18:43–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Djamgoz MB, Coombes RC and Schwab A: Ion
transport and cancer: From initiation to metastasis. Philos Trans R
Soc Lond B Biol Sci. 369:201300922014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koltai T: Cancer: Fundamentals behind pH
targeting and the double-edged approach. Onco Targets Ther.
9:6343–6360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brackenbury WJ: Voltage-gated sodium
channels and metastatic disease. Channels. 6:352–361. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roger S, Besson P and Le Guennec JY:
Involvement of a novel fast inward sodium current in the invasion
capacity of a breast cancer cell line. Biochim Biophys Acta.
1616:107–111. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fraser SP, Diss JK, Chioni AM, Mycielska
ME, Pan H, Yamaci RF, Pani F, Siwy Z, Krasowska M, Grzywna Z, et
al: Voltage-gated sodium channel expression and potentiation of
human breast cancer metastasis. Clin Cancer Res. 11:5381–5389.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Onganer PU, Seckl MJ and Djamgoz MB:
Neuronal characteristics of small-cell lung cancer. Br J Cancer.
93:1197–1201. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Diaz D, Delgadillo DM, Hernández-Gallegos
E, Ramírez-Domínguez ME, Hinojosa LM, Ortiz CS, Berumen J, Camacho
J and Gomora JC: Functional expression of voltage-gated sodium
channels in primary cultures of human cervical cancer. J Cell
Physiol. 210:469–478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao R, Shen Y, Cai J, Lei M and Wang Z:
Expression of voltage-gated sodium channel α subunit in human
ovarian cancer. Oncol Rep. 23:1293–1299. 2010.PubMed/NCBI
|
|
16
|
Guzel RM, Ogmen K, Ilieva KM, Fraser SP
and Djamgoz MBA: Colorectal cancer invasiveness in vitro:
Predominant contribution of neonatal Nav1.5 under normoxia and
hypoxia. J Cell Physiol. 234:6582–6593. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
House CD, Vaske CJ, Schwartz AM, Obias V,
Frank B, Luu T, Sarvazyan N, Irby R, Strausberg RL, Hales TG, et
al: Voltage-gated Na+ channel SCN5A is a key
regulator of a gene transcriptional network that controls colon
cancer invasion. Cancer Res. 70:6957–6967. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma RSY, Kayani K, Whyte-Oshodi D,
Whyte-Oshodi A, Nachiappan N, Gnanarajah S and Mohammed R: Voltage
gated sodium channels as therapeutic targets for chronic pain. J
Pain Res. 12:2709–2722. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Utrilla RG, Nieto-Marín P, Alfayate S,
Tinaquero D, Matamoros M, Pérez-Hernández M, Sacristán S, Ondo L,
de Andrés R, Díez-Guerra FJ, et al: Kir2. 1-Nav1. 5 channel
complexes are differently regulated than Kir2. 1 and Nav1. 5
channels alone. Front Physiol. 8:9032017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Onkal R, Mattis JH, Fraser SP, Diss JK,
Shao D, Okuse K and Djamgoz MB: Alternative splicing of Nav1.5: An
electrophysiological comparison of ‘neonatal’ and ‘adult’ isoforms
and critical involvement of a lysine residue. J Cell Physiol.
216:716–726. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamaci RF, Fraser SP, Battaloglu E, Kaya
H, Erguler K, Foster CS and Djamgoz MBA: Neonatal Nav1.5 protein
expression in normal adult human tissues and breast cancer. Pathol
Res Pract. 213:900–907. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ben-Porath I, Thomson MW, Carey VJ, Ge R,
Bell GW, Regev A and Weinberg RA: An embryonic stem cell-like gene
expression signature in poorly differentiated aggressive human
tumors. Nat Genet. 40:499–507. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brackenbury WJ, Chioni AM, Diss JK and
Djamgoz MB: The neonatal splice variant of Nav1.5 potentiates in
vitro invasive behaviour of MDA-MB-231 human breast cancer cells.
Breast Cancer Res Treat. 101:149–160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Isbilen B, Fraser SP and Djamgoz MB:
Docosahexaenoic acid (omega-3) blocks voltage-gated sodium channel
activity and migration of MDA-MB-231 human breast cancer cells. Int
J Biochem Cell Biol. 38:2173–2182. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Erdogan MA and Ozpolat B: Targeting of
Voltage-gated sodium channel NaV1. 5 inhibits cell
proliferation and colony formation in breast and ovarian cancer
cells. Cancer Res. 73 (8 Suppl):2013.doi:
10.1158/1538-7445.AM2013-514.
|
|
26
|
Nelson M, Yang M, Millican-Slater R and
Brackenbury WJ: Nav1.5 regulates breast tumor growth and metastatic
dissemination in vivo. Oncotarget. 6:32914–32929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar
|
|
28
|
Norsa'adah B: Univariable Analyses Using
IBM SPSS statistics version 20.0, Universiti Sains Malaysia,
Malaysia. 2013.
|
|
29
|
George D and Mallery P: Chapter 7:
Descriptive Statistics. SPSS for Windows Step by Step: a Simple
Study Guide and Reference 17.0 Update. 10th edition. Pearson;
Boston, MA: 2010
|
|
30
|
Schmider E, Ziegler M, Danay E, Beyer L
and Bühner M: Is it really robust? Reinvestigating the robustness
of ANOVA against violations of the normal distribution.
Methodology. 6:147–151. 2010. View Article : Google Scholar
|
|
31
|
Breen EJ, Tan W and Khan A: The
statistical value of raw fluorescence signal in Luminex xMAP Based
Multiplex Immunoassays. Sci Rep. 6:26996. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rhana P, Trivelato RRJ, Beirao PSL, Cruz
JS and Rodrigues ALP: Is there a role for voltage-gated
Na+ channels in the aggressiveness of breast cancer?
Braz J Med Biol Res. 50:e60112017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pagani O, Senkus E, Wood W, Colleoni M,
Cufer T, Kyriakides S, Costa A, Winer EP and Cardoso F; ESO-MBC
Task Force, : International guidelines for management of metastatic
breast cancer: Can metastatic breast cancer be cured? J Natl Cancer
Inst. 102:456–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Waks AG and Winer EP: Breast cancer
treatment: A review. JAMA. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fujii T, Le Du F, Xiao L, Kogawa T,
Barcenas CH, Alvarez RH, Valero V, Shen Y and Ueno NT:
Effectiveness of an adjuvant chemotherapy regimen for early-stage
breast cancer: A systematic review and network meta-analysis. JAMA
Oncol. 1:1311–1318. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Krug D: Adjuvant radiotherapy for breast
cancer: More than meets the eye. Breast Care (Basel). 15:109–111.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tremont A, Lu J and Cole JT: Endocrine
therapy for early breast cancer: Updated review. Ochsner J.
17:405–411. 2017.PubMed/NCBI
|
|
38
|
Munagala R, Aqil F and Gupta RC: Promising
molecular targeted therapies in breast cancer. Indian J Pharmacol.
43:236–245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
U.S Food and Drug Administration (FDA), .
FDA approves Atezolizumab for PD-L1 positive unresectable locally
advanced or metastatic triple-negative breast cancer. Retrieved
from. simplehttps://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative
|
|
40
|
Zurrida S, Bassi F, Arnone P, Martella S,
Del Castillo A, Ribeiro Martini R, Semenkiw ME and Caldarella P:
The changing face of mastectomy (from Mutilation to Aid to Breast
Reconstruction). Int J Surg Oncol. 2011:9801582011.PubMed/NCBI
|
|
41
|
Evans RL, Pottala JV, Nagata S and Egland
KA: Longitudinal autoantibody responses against tumor-associated
antigens decrease in breast cancer patients according to treatment
modality. BMC Cancer. 18:1192018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Witkowska AM: On the role of sIL-2R
measurements in rheumatoid arthritis and cancers. Mediators
Inflamm. 2005:121–130. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lundin K, Tuukkanen AM, Jansson C,
Nordström T and Lindqvist C: No soluble common cytokine receptor
gamma chain (gamma(c)) in activated human lymphocyte
cultures-comparison with soluble IL-2Ralpha. Immunol Lett.
82:235–240. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gotoh Y, Okamoto Y, Uemura O, Mori N,
Tanaka S, Ando T and Nishida M: Determination of age-related
changes in human soluble interleukin 2 receptor in body fluids of
normal subjects as a control value against disease states. Clin
Chim Acta. 289:89–97. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mougiakakos D, Choudhury A, Lladser A,
Kiessling R and Johansson CC: Regulatory T cells in cancer. Adv
Cancer Res. 107:57–117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dwarakanath BS, Farooque A and Gupta S:
Targeting regulatory T cells for improving cancer therapy:
Challenges and prospects. Cancer Rep (Hoboken). 1:e211052018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Halvorsen EC, Hamilton MJ, Young A,
Wadsworth BJ, LePard NE, Lee HN, Firmino N, Collier JL and
Bennewith KL: Maraviroc decreases CCL8-mediated migration of
CCR5+ regulatory T cells and reduces metastatic tumor
growth in the lungs. Oncoimmunology. 5:e11503982016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shang B and Liu Y, Jiang SJ and Liu Y:
Prognostic value of tumor-infiltrating FoxP3+ regulatory
T cells in cancers: A systematic review and meta-analysis. Sci Rep.
5:151792015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sakaguchi S, Sakaguchi N, Asano M, Itoh M
and Toda M: Immunologic self-tolerance maintained by activated T
cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a
single mechanism of self-tolerance causes various autoimmune
diseases. J Immunol. 155:1151–1164. 1995.PubMed/NCBI
|
|
50
|
Wei S, Kryczek I, Edwards RP, Zou L,
Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B, et al:
Interleukin-2 administration alters the
CD4+FOXP3+ T-cell pool and tumor trafficking
in patients with ovarian carcinoma. Cancer Res. 67:7487–7494. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu S and Sun X, Luo J, Zhu H, Yang X, Guo
Q, Song Y and Sun X: Effects of radiation on T regulatory cells in
normal states and cancer: Mechanisms and clinical implications. Am
J Cancer Res. 5:3276–3285. 2015.PubMed/NCBI
|
|
52
|
Yu P, Lee Y, Liu W, Krausz T, Chong A,
Schreiber H and Fu YX: Intratumor depletion of CD4+
cells unmasks tumor immunogenicity leading to the rejection of
late-stage tumors. J Exp Med. 201:779–791. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nishikawa H, Kato T, Tanida K, Hiasa A,
Tawara I, Ikeda H, Ikarashi Y, Wakasugi H, Kronenberg M, Nakayama
T, et al: CD4+ CD25+ T cells responding to
serologically defined autoantigens suppress antitumor immune
responses. Proc Natl Acad Sci USA. 100:10902–10906. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rech AJ and Vonderheide RH: Clinical use
of Anti-CD25 antibody daclizumab to enhance immune responses to
tumor antigen vaccination by targeting regulatory T cells. Ann N Y
Acad Sci. 1174:99–106. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wu L, Yun Z, Tagawa T, Rey-McIntyre K,
Anraku M and Perrot M: Tumor cell repopulation between cycles of
chemotherapy is inhibited by regulatory T-cell depletion in a
murine mesothelioma model. J Thorac Oncol. 6:1578–1586. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lissoni P, Brivio F, Fumagalli L, Messina
G, Meregalli S, Porro G, Rovelli F, Vigorè L, Tisi E and D'Amico G:
Effects of the conventional antitumor therapies surgery,
chemotherapy, radiotherapy and immunotherapy on regulatory T
lymphocytes in cancer patients. Anticancer Res. 29:1847–1852.
2009.PubMed/NCBI
|
|
57
|
Esquivel-Velázquez M, Ostoa-Saloma P,
Palacios-Arreola MI, Nava-Castro KE, Castro JI and Morales-Montor
J: The role of cytokines in breast cancer development and
progression. J Interferon Cytokine Res. 35:1–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Benoy IH, Salgado R, Van Dam P, Geboers K,
Van Marck E, Scharpé S, Vermeulen PB and Dirix LY: Increased serum
interleukin-8 in patients with early and metastatic breast cancer
correlates with early dissemination and survival. Clin Cancer Res.
10:71572004. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Singh JK, Farnie G, Bundred NJ, Simões BM,
Shergill A, Landberg G, Howell SJ and Clarke RB: Targeting CXCR1/2
significantly reduces breast cancer stem cell activity and
increases the efficacy of inhibiting HER2 via HER2-dependent and
-independent mechanisms. Clin Cancer Res. 19:643–656. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chang Q, Bournazou E, Sansone P, Berishaj
M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al:
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and
metastasis. Neoplasia. 15:848–862. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Masjedi A, Hashemi V, Hojjat-Farsangi M,
Ghalamfarsa G, Azizi G, Yousefi M and Jadidi-Niaragh F: The
significant role of interleukin-6 and its signaling pathway in the
immunopathogenesis and treatment of breast cancer. Biomed
Pharmacother. 108:1415–1424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lin S, Gan Z, Han K, Yao Y and Min D:
Interleukin-6 as a prognostic marker for breast cancer: A
meta-analysis. Tumori. 101:535–541. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Shibayama O, Yoshiuchi K, Inagaki M,
Matsuoka Y, Yoshikawa E, Sugawara Y, Akechi T, Wada N, Imoto S,
Murakami K, et al: Association between adjuvant regional
radiotherapy and cognitive function in breast cancer patients
treated with conservation therapy. Cancer Med. 3:702–709. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wolczyk D, Zaremba-Czogalla M,
Hryniewicz-Jankowska A, Tabola R, Grabowski K, Sikorski AF and
Augoff K: TNF-α promotes breast cancer cell migration and enhances
the concentration of membrane-associated proteases in lipid rafts.
Cell Oncol (Dordr). 39:353–363. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Osawa Y, Nagaki M, Banno Y, Brenner DA,
Asano T, Nozawa Y, Moriwaki H and Nakashima S: Tumor necrosis
factor alpha-induced interleukin-8 production via NF-kappaB and
phosphatidylinositol 3-kinase/Akt pathways inhibits cell apoptosis
in human hepatocytes. Infect Immun. 70:6294–6301. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kulbe H, Hagemann T, Szlosarek PW,
Balkwill FR and Wilson JL: The inflammatory cytokine tumor necrosis
factor-alpha regulates chemokine receptor expression on ovarian
cancer cells. Cancer Res. 65:10355–10362. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sheikhpour E, Noorbakhsh P, Foroughi E,
Farahnak S, Nasiri R and Neamatzadeh H: A survey on the role of
interleukin-10 in breast cancer: A narrative. Rep Biochem Mol Biol.
7:30–37. 2018.PubMed/NCBI
|
|
68
|
Li Y, Gao P, Yang J, Yu H, Zhu Y and Si W:
Relationship between IL-10 expression and prognosis in patients
with primary breast cancer. Tumour Biol. 35:11533–11540. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Dutta P, Sarkissyan M, Paico K, Wu Y and
Vadgama JV: MCP-1 is overexpressed in triple-negative breast
cancers and drives cancer invasiveness and metastasis. Breast
Cancer Res Treat. 170:477–486. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lim SY, Yuzhalin AE, Gordon-Weeks AN and
Muschel RJ: Targeting the CCL2-CCR2 signaling axis in cancer
metastasis. Oncotarget. 7:28697–28710. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kitamura T, Qian BZ, Soong D, Cassetta L,
Noy R, Sugano G, Kato Y, Li J and Pollard JW: CCL2-induced
chemokine cascade promotes breast cancer metastasis by enhancing
retention of metastasis-associated macrophages. J Exp Med.
212:1043–1059. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Low-Marchelli JM, Ardi VC, Vizcarra EA,
van Rooijen N, Quigley JP and Yang J: Twist1 induces CCL2 and
recruits macrophages to promote angiogenesis. Cancer Res.
73:662–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Qian BZ, Li J, Zhang H, Kitamura T, Zhang
J, Campion LR, Kaiser EA, Snyder LA and Pollard JW: CCL2 recruits
inflammatory monocytes to facilitate breast-tumor metastasis.
Nature. 475:222–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Andrikopoulos P, Fraser SP, Patterson L,
Ahmad Z, Burcu H, Ottaviani D, Diss JK, Box C, Eccles SA and
Djamgoz MB: Angiogenic functions of voltage-gated Na+
channels in human endothelial cells: Modulation of vascular
endothelial growth factor (VEGF) signaling. J Biol Chem.
286:16846–16860. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Fiorio Pla A and Munaron L: Functional
properties of ion channels and transporters in tumor
vascularization. Philos Trans R Soc Lond B Biol Sci.
369:201301032014. View Article : Google Scholar
|
|
76
|
Andrikopoulos P, Baba A, Matsuda T,
Djamgoz MBA, Yaqoob MM and Eccles SA: Ca2+ influx
through reverse mode Na+/Ca2+ exchange is
critical for vascular endothelial growth factor-mediated
extracellular signal-regulated kinase (ERK) 1/2 activation and
angiogenic functions of human endothelial cells. J Biol Chem.
286:37919–37931. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ginestier C, Liu S, Diebel ME, Korkaya H,
Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum
D, Guan JL, et al: CXCR1 blockade selectively targets human breast
cancer stem cells in vitro and in xenografts. J Clin Invest.
120:485–497. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Todorović-Raković N and Milovanović J:
Interleukin-8 in breast cancer progression. J Interferon Cytokine
Res. 33:563–570. 2013. View Article : Google Scholar : PubMed/NCBI
|
